Form 4: Vir Biotechnology Director Norbert Bischofberger Acquires 8,000 RSUs and 16,000 Stock Options

Vir Biotechnology, Inc. Director Norbert Bischofberger has acquired 8,000 restricted stock units and 16,000 stock options, which are set to vest in May 2026.

Summary

• Norbert W. Bischofberger, a Director of Vir Biotechnology, Inc. (VIR), acquired 8,000 restricted stock units (RSUs) on May 30, 2025.
• These RSUs were acquired at a price of $0 and are part of the Issuer's Equity Incentive Plan.
• The 8,000 RSUs will vest in full on May 30, 2026.
• Following this transaction, Mr. Bischofberger beneficially owns 24,000 shares of Common Stock directly.
• Additionally, Mr. Bischofberger acquired 16,000 stock options on May 30, 2025, with an exercise price of $4.94 per share.
• These stock options were acquired at a price of $0 and will vest and become exercisable in full on May 30, 2026.
• The stock options have an expiration date of May 29, 2035.
• Following this transaction, Mr. Bischofberger beneficially owns 16,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The acquisition of equity awards by a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. However, it's a routine compensation event rather than a direct open-market purchase, so the positive sentiment is moderate.

Positives

• Acquisition of 8,000 Restricted Stock Units (RSUs) by a Director, aligning management's interests with shareholders.
• Grant of 16,000 stock options to a Director, providing an incentive for long-term performance.
• The exercise price of the stock options ($4.94) provides a clear benchmark for future stock performance.

Negatives

• No direct cash purchase of shares by the director, as the acquisitions are RSU grants and option grants, which are common forms of equity compensation rather than open market purchases.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance beyond the vesting schedule of the equity awards.

Industry Context

This transaction is a routine equity compensation grant to a director in the biotechnology industry. Such grants are common for aligning executive and director interests with long-term company performance, particularly in R&D-intensive sectors like biotech where long development cycles are typical.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options as part of director compensation is a standard practice across the biotechnology and broader corporate sectors, aligning director incentives with shareholder value creation.
• The vesting schedule of approximately one year (May 2025 to May 2026) for these awards is typical for annual grants, providing a short-to-medium term retention and performance incentive.
• The exercise price of $4.94 for the stock options would typically be the closing price of Vir Biotechnology (VIR) stock on the grant date, which is standard for non-qualified stock options.
• Compared to other biotech companies, equity compensation forms a significant part of director and executive pay, reflecting the high-growth, high-risk nature of the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with long-term shareholder value, as the awards vest based on continued service and the options gain value with stock price appreciation.

Next Steps

• The 8,000 Restricted Stock Units (RSUs) are scheduled to vest in full on May 30, 2026.
• The 16,000 stock options are scheduled to vest and become exercisable in full on May 30, 2026.
• The stock options will expire on May 29, 2035.

Key Dates

Recommendation

Keywords

Vir Biotechnology, VIR, SEC Form 4, Insider Trading, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals